ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1948

Impact of Race on Hospitalization Outcomes for Goodpasture Syndrome in the United States

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Medaura, Juan Antonio, Division of Nephrology, Department of Internal Medicine,University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Thongprayoon, Charat, Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
  • Mao, Michael A., Department of Medicine, Mayo Clinic,, Jacksonville, Florida, United States
  • Boonpheng, Boonphiphop, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States
  • Kaewput, Wisit, Phramongkutklao College of Medicine, Bangkok, Thailand
  • Cheungpasitporn, Wisit, Division of Nephrology, Department of Internal Medicine,University of Mississippi Medical Center, Jackson, Mississippi, United States
Background

Goodpasture’s syndrome is a rare and life-threatening autoimmune disease. While Goodpasture’s syndrome is well described in Caucasian and Asian populations, its prevalence and outcomes among African American and Hispanic populations are unclear. We conducted this study to assess the impacts of race on hospital outcomes among patients with Goodpasture’s syndrome.

Methods

The National Inpatient Sample database was used to identify hospitalized patients with a principal diagnosis of Goodpasture’s syndrome from 2003-2014. Goodpasture’s syndrome patients were grouped based on their race. The differences in-hospital treatments and outcomes between Caucasian, African American, and Hispanic Goodpasture’s syndrome patients were assessed using logistic regression analysis.

Results

964 patients were hospitalized with a primarily diagnosis of Goodpasture’s syndrome. Of these, 786 were included in the analysis: 622 (65%) were Caucasian, 73 (8%) were African American, and 91 (9%) were Hispanic. The need for mechanical ventilation, non-invasive ventilation support, and renal replacement therapy in African Americans and Hispanics were comparable to Caucasians. There was no significant difference in organ failure, sepsis, and in-hospital mortality between African Americans and Caucasians. In contrast, Hispanics had higher in-hospital mortality than Caucasians but similar risk of organ failure and sepsis.

Conclusion

African American and Hispanic populations account for 8% and 9% of hospitalizations for Goodpasture’s syndrome, respectively. While there is no significant difference in in-hospital mortality between African Americans and Caucasians, Hispanics with Goodpasture’s syndrome carry a higher in-hospital mortality compared to Caucasians.